- Stocks
- Healthcare
- NASDAQ: VRTX

Price (delayed)

$229.68

Market cap

$58.4B

P/E Ratio

27.28

Dividend/share

N/A

EPS

$8.42

Enterprise value

$53B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather

Vertex Pharmaceuticals's quick ratio has increased by 22% YoY

The gross profit has grown by 19% YoY and by 7% from the previous quarter

The price to earnings (P/E) is 60% less than the 5-year quarterly average of 68.0 but 20% more than the last 4 quarters average of 22.7

The EPS has declined by 19% year-on-year but it has increased by 10% since the previous quarter

VRTX's debt has soared by 60% YoY

What are the main financial stats of VRTX

Market
Valuations
Earnings

Shares outstanding

254.25M

Market cap

$58.4B

Enterprise value

$53B

Price to earnings (P/E)

27.28

Price to book (P/B)

6.25

Price to sales (P/S)

8.31

EV/EBIT

18.86

EV/EBITDA

18.08

EV/Sales

7.43

Revenue

$7.13B

EBIT

$2.81B

EBITDA

$2.93B

Free cash flow

$1.92B

Per share
Balance sheet
Liquidity

EPS

$8.42

Free cash flow per share

$7.44

Book value per share

$36.74

Revenue per share

$27.65

TBVPS

$43.5

Total assets

$12.62B

Total liabilities

$3.09B

Debt

$876.8M

Equity

$9.53B

Working capital

$6.94B

Debt to equity

0.09

Current ratio

4.62

Quick ratio

4.21

Net debt/EBITDA

-1.84

Margins
Efficiency
Dividend

EBITDA margin

41.1%

Gross margin

87.9%

Net margin

30.5%

Operating margin

37.2%

Return on assets

17.9%

Return on equity

23.9%

Return on invested capital

77.8%

Return on capital employed

26.3%

Return on sales

39.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Vertex Pharmaceuticals stock price performed over time

Intraday

0.7%

1 week

-1.87%

1 month

2.79%

1 year

-3.33%

YTD

4.59%

QTD

4.59%

How have Vertex Pharmaceuticals's revenue and profit performed over time

Revenue

$7.13B

Gross profit

$6.27B

Operating income

$2.65B

Net income

$2.18B

Gross margin

87.9%

Net margin

30.5%

VRTX's net margin is down by 32% YoY but it is up by 2.3% QoQ

The gross profit has grown by 19% YoY and by 7% from the previous quarter

Vertex Pharmaceuticals's net income has decreased by 19% YoY but it has increased by 9% QoQ

VRTX's revenue is up by 19% YoY and by 7% QoQ

What is Vertex Pharmaceuticals's growth rate over time

What is Vertex Pharmaceuticals stock price valuation

P/E

27.28

P/B

6.25

P/S

8.31

EV/EBIT

18.86

EV/EBITDA

18.08

EV/Sales

7.43

The price to earnings (P/E) is 60% less than the 5-year quarterly average of 68.0 but 20% more than the last 4 quarters average of 22.7

The EPS has declined by 19% year-on-year but it has increased by 10% since the previous quarter

The stock's price to book (P/B) is 47% less than its 5-year quarterly average of 11.9 but 4.2% more than its last 4 quarters average of 6.0

The equity has grown by 17% YoY and by 3.6% from the previous quarter

The price to sales (P/S) is 37% less than the 5-year quarterly average of 13.1

VRTX's revenue is up by 19% YoY and by 7% QoQ

How efficient is Vertex Pharmaceuticals business performance

The return on equity has declined by 37% year-on-year but it has grown by 4.8% since the previous quarter

VRTX's return on assets is down by 36% year-on-year but it is up by 7% since the previous quarter

The return on invested capital has declined by 23% year-on-year but it rose by 7% since the previous quarter

The return on sales has declined by 20% year-on-year but it has increased by 6% since the previous quarter

What is VRTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for VRTX.

How did Vertex Pharmaceuticals financials performed over time

Vertex Pharmaceuticals's current ratio has increased by 24% YoY

Vertex Pharmaceuticals's quick ratio has increased by 22% YoY

VRTX's debt is 91% lower than its equity

VRTX's debt has soared by 60% YoY

The debt to equity rose by 29% YoY but it fell by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.